Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor.

Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommended for enhancing its efficacy in patients with inflammatory bowel disease (IBD). However, IFX concentrations are currently determined in patients' serum/plasma, which requires sample preparation from blood, hence hampering the turnaround time. In this paper, we present a short immunoassay (10 min) using a fiber-optic surface plasmon resonance (FO-SPR) biosensor for detection of IFX spiked in 100-fold diluted serum, plasma, and whole blood. The calculated limits of detection (LOD) based on calibration curves were 1.42, 1.00, and 1.34 ng/mL, respectively, which coincides with expected IFX concentrations in diluted samples from IBD patients. A linear correlation was established among different matrixes, indicating that the matrix effect was insignificant. The established point-of-care (POC) FO-SPR bioassay was also used to measure IFX in 100-fold diluted extracts of dried blood spots (DBS), and LOD achieved was below 2 ng/mL. Although DBS might be ideal for POC, this is the first report of using an SPR biosensor for measuring DBS samples. Finally, the POC FO-SPR immunoassay was validated by using matching serum and plasma samples from five IBD patients. A Pearson correlation of 0.968 was obtained between serum and plasma samples. IFX concentrations determined with FO-SPR were compared to a clinically validated enzyme-linked immunosorbent assay (ELISA), resulting in excellent Pearson correlation and intraclass correlation coefficient, both being 0.99 for serum and plasma samples. In conclusion, this paper demonstrates that our FO-SPR biosensor can be used as a true POC diagnostic tool for determining IFX concentrations in a variety of matrixes.

[1]  Brian Whiting,et al.  THERAPEUTIC DRUG MONITORING , 1985, The Lancet.

[2]  Betti Maria,et al.  Analytical and Bioanalytical Chemistry - Plasma Spectrochemistry , 2007 .

[3]  M. Picot,et al.  Dried blood spot for hepatitis C virus serology and molecular testing , 2009, Hepatology.

[4]  J. McElnay,et al.  Development and validation of a dried blood spot–HPLC assay for the determination of metronidazole in neonatal whole blood samples , 2010, Analytical and bioanalytical chemistry.

[5]  A. Rehemtulla,et al.  Molecular Imaging , 2009, Methods in Molecular Biology.

[6]  Sharon Williams,et al.  What a drop can do: Dried blood spots as a minimally invasive method for integrating biomarkers into population-based research , 2007, Demography.

[7]  J. Alffenaar,et al.  Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  Valerie A Longo,et al.  Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. , 2013, Molecular imaging.

[9]  H. Tanke,et al.  A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study , 2013, Analytical and Bioanalytical Chemistry.

[10]  Peter E. Wright,et al.  Modulation of allostery by protein intrinsic disorder , 2013, Nature.

[11]  Nuno M Reis,et al.  A lab-in-a-briefcase for rapid prostate specific antigen (PSA) screening from whole blood. , 2014, Lab on a chip.

[12]  Els Brouwers,et al.  Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays , 2015, Therapeutic drug monitoring.

[13]  J. Lammertyn,et al.  Improved surface plasmon resonance biosensing using silanized optical fibers , 2015 .

[14]  C. Stove,et al.  Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. , 2015, Bioanalysis.

[15]  H. Guchelaar,et al.  Dried blood spot analysis for therapeutic drug monitoring of pazopanib , 2015, Journal of clinical pharmacology.

[16]  Jeroen Lammertyn,et al.  Transferability of antibody pairs from ELISA to fiber optic surface plasmon resonance for infliximab detection , 2015, Photonics West - Biomedical Optics.

[17]  S. Vermeire,et al.  Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. , 2016, Biosensors & bioelectronics.

[18]  S. Vermeire,et al.  Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation , 2016, Clinical and translational gastroenterology.